Skip to main content

Table 3 Rates of irAEs in the Italian Early Access Program of nivolumab in mRCC

From: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

irAEs G1
N (%)
G2
N (%)
G3
N (%)
G4
N (%)
Any grade
N (%)
Cutaneous 16 (4) 12 (3) 2 (1) 0 30 (8)
Endocrine 10 (3) 5 (1) 1 (< 1) 1 (< 1) 17 (4)
Hepatic 5 (1) 2 (1) 0 0 7 (2)
Gastro-intestinal 8 (2) 7 (2) 4 (1) 0 19 (5)
Pulmonary 1 (< 1) 1 (< 1) 2 (1) 0 4 (1)
  1. Abbreviations: N number, irAEs immune-related adverse events